CCR8 expectations | ApexOnco - Clinical Trials news and analysis The combo approach is also being investigated within single molecules: Biotheus is developing bispecifics combining CCR8 with TIGIT antagonism and with CTLA-4 blockade, but for now these remain preclinical Other preclinical anti-CCR8 MAbs include FibroGen’s FG-3175 and Domain Therapeutics’ DT-7012
AACR 2025 CHS-114 poster_v9_FINAL updated - coherus. com Tumor types in which clinical benefit has been observed with anti-CCR8 antibodies (CHS-114-101 study or competitor trials) are highlighted (red circles) For evaluating CCR8+ Tregs, CCR8 and FOXP3 staining was performed
Study Details | A First-in-human Study to Learn How Safe the Study Drug . . . These dates track the progress of study record and summary results submissions to ClinicalTrials gov Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website
Coherus Presents Promising Early Clinical Data from Phase 1 Results from Phase 1b dose expansion trial evaluating CHS-114 monotherapy and with toripalimab in HNSCC This open-label Phase 1b clinical trial evaluated CHS-114 as a single-agent and in